Analysts Issue Forecasts for TSE:CPH FY2025 Earnings

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) – Equities research analysts at Leede Financial decreased their FY2025 EPS estimates for Cipher Pharmaceuticals in a research report issued on Friday, November 8th. Leede Financial analyst D. Loe now expects that the company will earn $0.93 per share for the year, down from their prior estimate of $1.02. Leede Financial currently has a “Hold” rating on the stock. The consensus estimate for Cipher Pharmaceuticals’ current full-year earnings is $1.29 per share. Leede Financial also issued estimates for Cipher Pharmaceuticals’ FY2026 earnings at $1.05 EPS and FY2027 earnings at $1.14 EPS.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last announced its quarterly earnings data on Thursday, November 7th. The company reported C$0.01 earnings per share for the quarter, missing the consensus estimate of C$0.03 by C($0.02). Cipher Pharmaceuticals had a net margin of 102.01% and a return on equity of 28.43%. The business had revenue of C$14.15 million during the quarter, compared to analyst estimates of C$13.37 million.

CPH has been the topic of several other reports. Stifel Canada upgraded shares of Cipher Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, August 12th. Stifel Nicolaus cut their price objective on shares of Cipher Pharmaceuticals from C$19.00 to C$17.00 in a report on Monday.

Cipher Pharmaceuticals Trading Up 0.1 %

Shares of TSE CPH opened at C$12.80 on Monday. The company’s 50 day simple moving average is C$15.95 and its 200 day simple moving average is C$12.33. Cipher Pharmaceuticals has a fifty-two week low of C$5.03 and a fifty-two week high of C$19.69. The firm has a market capitalization of C$327.55 million, a P/E ratio of 10.24 and a beta of 1.20. The company has a debt-to-equity ratio of 0.33, a current ratio of 11.18 and a quick ratio of 2.67.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.